Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

14.10 EUR

0.00 %

5,599 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

0.00 %
-0.35 %
+11.02 %
+41.85 %
+78.48 %
+110.45 %
+229.05 %
+158.01 %
-97.67 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
101.71M EUR
Turnover
199.08K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Reduce
Target price
Updated
18.08.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 18.08.2025

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
New Advanced Treatment for Depression, OCD, Pain, and Stroke in Denmark A completely new and advanced form of treatment using targeted magnetic therapy is designed to help patients suffering from depression, obsessive-compulsive disorder, pain, and mild post-stroke symptoms. The ...
23 hours ago
by Kyhnykeisari
33
Vejle Amts Folkeblad – 14 Dec 25 Privathospitalet Mølholm er de første i Danmark: Dorte får færre smerter med... Som den første i Danmark har Dorte Michelsen Jessen fået en ny, præcis hjernestimulering, der allerede har løsnet grebet om de nervesmerter, hun har levet med i årevis...
19 hours ago
by Kyhnykeisari
29
This morning’s announcement, in my opinion, only confirms once again that Nexstim only announces deals from its own pipeline, which therefore includes therapy, research, and Finland. Diagnostic deals have completely disappeared from announcements since September (that too was NBS5...
23 hours ago
by Tim89
11
The reported device is a therapy machine, meaning it is not a Brainlab sale. In my opinion, no unambiguous conclusions can still be drawn from that, other than that Brainlab sales have still not been reported as understood.
23 hours ago
by Hannu
11
Oh wow, two devices for the day. We’ll get surprises for the advent calendar after all!
21 minutes ago
by Apesor
10
Here is the announcement, gentlemen! nexstim.com Nexstim - Press-release
12 minutes ago
by Umpi
6
It has also been separately noted many times regarding Brainlab deals that it takes several years before a deal starts to operate at the desired level. From the first contact to closing a deal, it takes an average of 18 months, and Brainlab’s sales team only started training this...
23 hours ago
by Kyhnykeisari
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.